Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2010-08-09
2011-12-06
Rawlings, Stephen (Department: 1643)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C530S350000, C530S387300, C530S387900, C530S388200
Reexamination Certificate
active
08071372
ABSTRACT:
The present invention provides Tumor Endothelial Marker 5α (TEM5α) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TEM5α polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, or prevention of diseases, disorders, and conditions associated with TEM5α polypeptides.
REFERENCES:
patent: 5763219 (1998-06-01), Keyomarsi
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0170838 (2003-09-01), Mishra et al.
Alberts et al., Molecular Biology of the Cell, Garland Publishing, Inc., pp. 5-7, 1994.
Bergers G.G. et al., “Extrinsic regulators of epithelial tumor progression: metalloproteinases.” Current Opinion in Genetics and Development, vol. 10 pp. 120-127, 2000.
Boehinger Mannheim Catalog, p. 557, 1991.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science 247, pp. 1306-1310 (1990).
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,” Journal of Cell Biology, vol. 111(5) Part1, pp. 2129-2138, Nov. 1990.
Colman, P.M. et al., “Effects of amino acid sequence changes on antibody-antigen interactions,” Research in Immunology, vol. 145, pp. 33-36, 1994.
Database Gene Bank, AN:AL529331, “Homo sapiens cDNA clone CS0DD002YN14,” Li, et al., Feb. 2001.
Database Gene Bank, AN:M88565, “Structure and Expression of the Human p58clk-1 Protein Kinase Chromosomal Gene,” Eipers et al., Jan. 1995.
Geraci, M.W., et al., “Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis,” Circ. Res. vol. 88, pp. 555-562, 2001.
Gene, T., “Systems for identifying new drugs are often faulty,” Science, vol. 278, pp. 1041-1042, 1997.
Hurwitz, et al., “Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer,” N. Engl. J. Med. vol. 350(23), pp. 2335-2342, 2004.
Ibragimova, G.T. and Eade, R.C., “Stability of the beta-sheet of the WW domain: A molecular dynamics simulation study,” Biophysical Journal, vol. 77(4), pp. 2191-2198, Oct. 1999.
Lazar, E. et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,” Molecular and Cellular Biology, vol. 8, No. 3, pp. 1247-1252, Mar. 1988.
Lin, M.C. et al., “Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon ,” Biochemistry USA, vol. 14(8), pp. 1559-1563, 1975.
Schwatz G.P., et al., “A superactive insulin: [B10-aspartic acid]insulin(human),” Proc. Natl. Acad. Sci. USA, vol. 84 (18), pp. 6408-6411, 1987.
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biology, vol. 18, pp. 34-39, 2000.
St. Croix, B. et al., “Genes expressed in human tumor endothelium,” Science, vol. 289(5482), pp. 1197-1202, Aug. 18, 2000.
Takamasa, I., et al., “Construction of Preferential cDNA Microarray Specialized for Human Colorectal Carcinoma: Molecular Sketch of Colorectal Cancer,” Biochem. Biophys. Res. Commun. vol. 285, pp. 1244-1249, 2001.
Tockman, M.S., et al., “Considerations in bringing a cancer biomarker to clinical application,” Cancer Research, vol. 52, pp. 2711s-2718s, 1992.
Vallon, Mario, et al., “Proteolytically Processed Soluble Tumor Endothelial Marker (TEM) 5 Mediates Endothelial Cell Survival during Angiogenesis by Linking Integrin v 3 to Glycosaminoglycans,” J. Biol. Chem., vol. 281(4), pp. 34179-34188, Nov. 10, 2006.
Villaret, Douglas B., et al., “Identification of Genes Overexpressed in Head and Neck Squamous Cell Carcinoma Using a Combination of Complementary DNA Subtraction and Microarray Analysis,” Laryngoscope, vol. 110, pp. 374-381, Mar. 2000.
Ward, Development Oncology, Nijhoff Publisher, vol. 21, pp. 91-106, 1985.
Wells, James A., “Additivity of Mutational Effects in Proteins,” Biochemistry, vol. 29, pp. 8509-8517, 1990.
Yamamoto, et al., “Direct binding of the human homologue of the drosophila disc large tumor suppressor gene to seven-pass thransmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein,” Oncogene, vol. 23, pp. 3889-3897, 2004.
Zhang, S., et al., “Microarray analysis of nicotine-induced changes in gene expression in endothelial cells Publication: Physiological genomics,” Physiol. Genomics, vol. 5, pp. 187-192, 2001.
Amgen Inc.
Lamerdin John A.
Rawlings Stephen
LandOfFree
Tumor endothelial marker 5α molecules and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor endothelial marker 5α molecules and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor endothelial marker 5α molecules and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4306553